| Identification | Back Directory | [Name]
TC-G 24 | [CAS]
1257256-44-2 | [Synonyms]
TC-G 24
TCG 24,TC G 24
N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine
1,3,4-Oxadiazol-2-amine, N-(3-chloro-4-methylphenyl)-5-(4-nitrophenyl)-
(3-Chloro-4-methyl-phenyl)-[5-(4-nitro-phenyl)-[1,3,4]oxadiazol-2-yl]-amine | [Molecular Formula]
C15H11ClN4O3 | [MOL File]
1257256-44-2.mol | [Molecular Weight]
330.73 |
| Chemical Properties | Back Directory | [Boiling point ]
502.9±60.0 °C(Predicted) | [density ]
1.437±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 10 mM in DMSO with gentle warming | [form ]
Powder | [pka]
-1.70±0.50(Predicted) | [color ]
yellow |
| Hazard Information | Back Directory | [Uses]
TC-G 24 is a novel GSK-3β inhibitor with potent in vitro and in vivo activities and excellent brain permeability. | [in vivo]
TC-G 24 (Compound 24) (0-15 mg/kg; i.p.; once) significantly raises liver glycogen content in a dose-dependent manner without obvious toxicity and can cross the BBB[1]. | Animal Model: | Six-week-old male C57BL/6N mice with weights averaging 22 g[1] | | Dosage: | 1, 5, and 15 mg/kg | | Administration: | Intraperitoneal injection, once | | Result: | Significantly raised liver glycogen content in a dose-dependent manner without obvious toxicity. Was detected in the brain at concentrations higher than in plasma for all three tested doses (38 ± 6, 113 ± 54 and 286 ± 58 ng/g brain tissue at 1, 5 and 15 mg/kg, respectively). |
| [IC 50]
GSK-3β: 17.1 nM (IC50) | [storage]
Store at +4°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
R&D Systems, Inc
|
| Tel: |
18003437475 18003437475 |
| Website: |
www.rndsystems.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|